First Trust Advisors LP Hutchmed (China) LTD Transaction History

First Trust Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$7.65 - $15.51 $245,763 - $498,274	-32,126 Reduced 42.13%	44,136 $652,000
Q3 2022 Nov 14, 2022	SELL	$8.63 - $15.52 $30,860 - $55,499	-3,576 Reduced 4.48%	76,262 $676,000
Q2 2022 Aug 12, 2022	BUY	$8.59 - $20.77 $685,808 - $1.66 Million	79,838 New	79,838 $1.01 Million
Q2 2019 Jul 30, 2019	SELL	$22.0 - $31.78 $480,612 - $694,265	-21,846 Closed	0 $0
Q1 2019 May 09, 2019	SELL	$21.27 - $30.58 $132,554 - $190,574	-6,232 Reduced 22.2%	21,846 $668,000
Q4 2018 Feb 07, 2019	BUY	$23.09 - $37.69 $648,321 - $1.06 Million	28,078 New	28,078 $648,000

8.25M

3.8K

2.4K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $3.11B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.